The third new crown oral drug was approved for marketing!

On December 30, the State Food and Drug Administration announced that on December 29, in accordance with the relevant provisions of the “Drug Administration Law” and in accordance with the special approval procedures for drugs, the State Food and Drug Administration conducted emergency review and approval, and conditionally approved Merck’s new crown virus Therapeutic drug Monogravir Capsules (trade name: LAGEVRIO) import registration. This is the third new crown oral drug approved in China after Pfizer Paxlovid (Nimatevir Tablets/Ritonavir Tablets) and Henan Real Bio Azvudine. | Related reading (The Paper)

Yu Tong

Recently, the peak of infection in Beijing has almost passed; the peak of severe illness is ushered in, and only when you are in it will you realize whether the preparations in the past three years before the release are right or not. The vaccination rate of the elderly is already an old problem. The biggest problem now is that Pfizer Paxlovid, which has undergone clinical trials and actual use, is still hard to find in Beijing. According to the Beijing community According to the rules of the hospital, it may be too late when you can enter the hospital and use this special medicine. After all, this medicine is only effective if you take it in the early stage of infection. Insufficient supply of specific medicines is an important reason why the peak of severe cases in Beijing is still lingering. Merck & Co.’s monogravir capsules have also been approved for marketing, which may be a remedy. A drop in the bucket.

This article is reproduced from: https://www.fortunechina.com/jingxuan/25677.htm
This site is only for collection, and the copyright belongs to the original author.